Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

International, Multicenter, Single-arm, Open-label, 12-week Phase IIIb Study to Evaluate RebiSmart™ Suitability for Self Injection of Rebif® New Formulation (RNF) in Multidose Cartridges in Patients With Relapsing Form of Multiple Sclerosis (RMS)

NCT00735007 is registered in ClinicalTrials.gov with EMD Serono as lead sponsor.

NCT NCT00735007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00735007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
International, Multicenter, Single-arm, Open-label, 12-week Phase IIIb Study to Evaluate RebiSmart™ Suitability for Self Injection of Rebif® New Formulation (RNF) in Multidose Cartridges in Patients With Relapsing Form of Multiple Sclerosis (RMS)
Lead sponsor
EMD Serono
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2008
Completion date
Not reported
Enrollment
106 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis